Multiple-dose pharmacokinetics of ceftibuten in healthy volunteers
- PMID: 7726497
- PMCID: PMC162542
- DOI: 10.1128/AAC.39.2.356
Multiple-dose pharmacokinetics of ceftibuten in healthy volunteers
Abstract
The pharmacokinetics of ceftibuten, a new cephalosporin antibiotic, and its conversion product, ceftibutentrans, were studied in healthy male volunteers following daily oral administration of a 400-mg capsule for 7 days. Mean concentrations of ceftibuten in plasma obtained on day 5 were similar to those obtained on day 7. Analysis of variance indicated that the concentrations in plasma on days 5 and 7 were at steady state. The mean accumulation factor was 1.14 for day 5 and 1.13 for day 7. The half-life (2.4 h) was independent of the duration of drug administration, and the mean maximum concentration of drug in plasma was 18 to 19 micrograms/ml. Urinary excretion was the major elimination route for ceftibuten, by which 57 to 59% of the drug was excreted unchanged over a 24-h period. The amounts of ceftibuten-trans in plasma and urine were low.
Similar articles
-
Pharmacokinetics and dose proportionality of ceftibuten in men.Antimicrob Agents Chemother. 1995 Feb;39(2):359-61. doi: 10.1128/AAC.39.2.359. Antimicrob Agents Chemother. 1995. PMID: 7726498 Free PMC article.
-
Multiple-dose pharmacokinetics of ceftibuten after oral administration to healthy volunteers.J Pharm Sci. 1994 Sep;83(9):1236-40. doi: 10.1002/jps.2600830910. J Pharm Sci. 1994. PMID: 7830237 Clinical Trial.
-
Multiple-Dose Pharmacokinetics of Ceftibuten in Healthy Adults and Geriatric Volunteers.Am J Ther. 1994 Jun;1(1):42-48. doi: 10.1097/00045391-199406000-00008. Am J Ther. 1994. PMID: 11835066
-
Pharmacokinetics of ceftibuten in children.Pediatr Infect Dis J. 1995 Jul;14(7 Suppl):S93-101. doi: 10.1097/00006454-199507001-00005. Pediatr Infect Dis J. 1995. PMID: 7567317 Review.
-
Ceftibuten: a new expanded-spectrum oral cephalosporin.Ann Pharmacother. 1997 Sep;31(9):1022-33. doi: 10.1177/106002809703100913. Ann Pharmacother. 1997. PMID: 9296244 Review.
Cited by
-
A phase I, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the pharmacokinetics, safety, and tolerability of oral ceftibuten in healthy adult subjects.Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0109923. doi: 10.1128/aac.01099-23. Epub 2023 Dec 7. Antimicrob Agents Chemother. 2024. PMID: 38059635 Free PMC article. Clinical Trial.
-
Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of Enterobacterales Expressing Extended-Spectrum β-Lactamases and Serine Carbapenemases.Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0055221. doi: 10.1128/AAC.00552-21. Epub 2021 Jul 16. Antimicrob Agents Chemother. 2021. PMID: 34001510 Free PMC article.
-
Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: a retrospective observational case-series.Eur J Clin Microbiol Infect Dis. 2018 Oct;37(10):2021-2025. doi: 10.1007/s10096-018-3338-z. Epub 2018 Aug 16. Eur J Clin Microbiol Infect Dis. 2018. PMID: 30117050
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources